1
|
Prakash S, Sahu A, Mishra D, Datta N, Mukherjee S. Determinants of Variable Total Platelet Count in Healthy Plateletpheresis Donor. Indian J Hematol Blood Transfus 2024; 40:448-453. [PMID: 39011268 PMCID: PMC11246351 DOI: 10.1007/s12288-023-01721-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 11/30/2023] [Indexed: 07/17/2024] Open
Abstract
The platelet count in a healthy individual varies between 150 and 450 × 109/L. This study explores the factors affecting this variation in platelet count in healthy blood donors selected for platelet donation. This retrospective study comprises an analysis of platelet donor data between the year 2016-2022. The pre-recorded donor details such as age, gender, blood group, body mass index (BMI), and complete blood counts were collected and analyzed using the software 'R' (version 4.1.0). The statistical analysis consists of a test of normalcy followed by descriptive details and advanced statistics such as correlation and regression analysis to predict the variables affecting platelet count. The p-value of less than 0.05 was taken as significant. The median (IQR) of hemoglobin, platelet count, and total leucocyte count (TLC) was 142(135-150) g/L, 239(204-285) × 109/L, and 7.6(6.4-8.8) × 109/L, respectively. The platelet count was positively correlated with TLC (p = 0.000) and negatively with the age of the platelet donor (p = 0.001). The Kruskal-Wallis test detected significant differences in the platelet count among the ABO blood group (p = 0.008). Further, regression analysis confirms the independent positive association of total platelet count with the total leucocyte count (p = 0.000) and the negative association of platelet count with age (p = 0.004). This study concludes the strong dependency of total platelet count with total leucocyte count, age, and blood group.
Collapse
Affiliation(s)
- Satya Prakash
- Department of Transfusion Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha India
| | - Ansuman Sahu
- Department of Transfusion Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha India
| | - Debasish Mishra
- Department of Transfusion Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha India
| | - Namrata Datta
- Department of Transfusion Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha India
| | - Somnath Mukherjee
- Department of Transfusion Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha India
| |
Collapse
|
2
|
Vargas-Alarcón G, Pérez-Méndez O, Posadas-Sánchez R, González-Pacheco H, Arias-Mendoza A, Escobedo G, Juárez-Cedillo T, Arellano-González M, Manuel Fragoso J. ABO gene polymorphisms are associated with acute coronary syndrome and with plasma concentration of HDL-cholesterol and triglycerides. BIOMOLECULES & BIOMEDICINE 2023; 23:1125-1135. [PMID: 37334748 PMCID: PMC10655879 DOI: 10.17305/bb.2023.9244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 06/10/2023] [Accepted: 06/10/2023] [Indexed: 06/20/2023]
Abstract
The role of ABO gene polymorphisms in acute coronary syndrome (ACS) and lipid metabolism is increasingly recognized. We investigated whether ABO gene polymorphisms are significantly associated with ACS and the plasma lipid profile. Six ABO gene polymorphisms (rs651007 T/C, rs579459 T/C, rs495928 T/C, rs8176746 T/G, rs8176740 A/T, and rs512770 T/C) were determined by 5'exonuclease TaqMan assays in 611 patients with ACS and 676 healthy controls. The results demonstrated that the rs8176746 T allele was associated with a lower risk of ACS under the co-dominant, dominant, recessive, over-dominant, and additive models (P = 0.0004, P = 0.0002, P = 0.039, P = 0.0009, and P = 0.0001, respectively). Furthermore, under co-dominant, dominant, and additive models, the rs8176740 A allele was associated with a lower risk of ACS (P = 0.041, P = 0.022, and P = 0.039, respectively). On the other hand, the rs579459 C allele was associated with a lower risk of ACS under the dominant, over-dominant, and additive models (P = 0.025, P = 0.035, and P = 0.037, respectively). In a subanalysis performed with the control group, rs8176746 T and rs8176740 A alleles were associated with low systolic blood pressure and with both high high-density lipoprotein-cholesterol (HDL-C) and low triglyceride plasma concentrations, respectively. In conclusion, ABO gene polymorphisms were associated with a lower risk of ACS, and lower systolic blood pressure and plasma lipid levels, suggesting a causal relationship between ABO blood groups and the incidence of ACS.
Collapse
Affiliation(s)
- Gilberto Vargas-Alarcón
- Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, México
| | - Oscar Pérez-Méndez
- Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, México
| | - Rosalinda Posadas-Sánchez
- Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, México
| | | | | | - Galileo Escobedo
- Unidad de Medicina Experimental, Hospital General de Mexico, Dr. Eduardo Liceaga, Mexico City, México
| | - Teresa Juárez-Cedillo
- Unidad de Investigación en Epidemiologia y Servicios de Salud-Área de Envejecimiento. Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social, Mexico City, México
| | - Marva Arellano-González
- Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, México
| | - José Manuel Fragoso
- Departamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, México
| |
Collapse
|
3
|
Shah RJ, Harimoorthy V, Khatwani G. ABO incompatibility: A cause for neonatal alloimmune thrombocytopenia. Asian J Transfus Sci 2023; 17:133-135. [PMID: 37188011 PMCID: PMC10180803 DOI: 10.4103/ajts.ajts_194_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 01/14/2022] [Indexed: 05/17/2023] Open
Abstract
ABO antibodies are naturally occurring antibodies. The ABO antibodies found in the Group O individuals include anti-A and anti-B. In Group O individuals, it tends to be predominantly immunoglobulins G (IgG), although immunoglobulins M and IgA components are also present. Infants of Group O mothers are at higher risk for hemolytic disease of the fetus and new-born than those born to mothers with Group A or B because IgG readily cross the placenta. At the same time, abnormal high concentration of ABO antibody in mother can lead to destruction of platelets in neonates and leads to development of neonatal alloimmune thrombocytopenia as human platelets carry detectable quantities of A and B blood group antigens on their surface. Proper and early diagnosis combined with treatment with intravenous immunoglobulins or transfusion with compatible platelets, may be from mother, can save the neonate from bleeding episodes.
Collapse
|
4
|
ABO Incompatibility between the Mother and Fetus Does Not Protect against Anti-Human Platelet Antigen-1a Immunization by Pregnancy. J Clin Med 2022; 11:jcm11226811. [PMID: 36431288 PMCID: PMC9694632 DOI: 10.3390/jcm11226811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 11/07/2022] [Accepted: 11/16/2022] [Indexed: 11/19/2022] Open
Abstract
(1) Background: ABO blood group incompatibility between the mother and fetus protects against anti-D immunization by pregnancy. The possible role of ABO incompatibility in protecting against anti-human platelet antigen-1a immunization is unclear. (2) Methods: This study retrospectively screened 817 families (mother-father-neonate trios) of suspected fetal and neonatal alloimmune thrombocytopenia for inclusion. ABO genotypes were determined in 118 mother-child pairs with confirmed alloimmune thrombocytopenia due to anti-HPA-1a antibodies, and 522 mother-child pairs served as the control group. The expression of blood group antigen A on platelets was determined in 199 consecutive newborns by flow cytometry and compared with adult controls. (3) Results: ABO incompatibility between mother and fetus did not protect against anti-human platelet antigen-1a immunization by pregnancy. ABO blood groups of mothers and/or fetuses were not associated with the severity of fetal and neonatal alloimmune thrombocytopenia. The expression pattern of blood group A antigens on the platelets of newborns mirrored that of adults, albeit on a lower level. Blood group A antigen was detected on a subpopulation of neonatal platelets, and some newborns revealed high platelet expression of A determinants on all platelets (type II high-expressers). (4) Conclusion: The lack of a protective effect of ABO incompatibility between mother and fetus against anti-human platelet antigen-1a immunization by pregnancy may indicate that fetal platelets are not the cellular source by which the mother is immunized.
Collapse
|
5
|
Mankelow TJ, Singleton BK, Moura PL, Stevens-Hernandez CJ, Cogan NM, Gyorffy G, Kupzig S, Nichols L, Asby C, Pooley J, Ruffino G, Hosseini F, Moghaddas F, Attwood M, Noel A, Cooper A, Arnold DT, Hamilton F, Hyams C, Finn A, Toye AM, Anstee DJ. Blood group type A secretors are associated with a higher risk of COVID-19 cardiovascular disease complications. ACTA ACUST UNITED AC 2021; 2:175-187. [PMID: 34124710 PMCID: PMC8176350 DOI: 10.1002/jha2.180] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 02/24/2021] [Accepted: 02/25/2021] [Indexed: 01/01/2023]
Abstract
The SARS-CoV-2 virus causes COVID-19, an infection capable of causing severe disease and death but which can also be asymptomatic or oligosymptomatic. We investigated whether ABO blood group or secretor status was associated with COVID-19 severity. We investigated secretor status because expression of ABO glycans on secreted proteins and non-erythroid cells are controlled by a fucosyltransferase (FUT2), and inactivating FUT2 mutations result in a non-secretor phenotype which protects against some viral infections. Data combined from healthcare records and our own laboratory tests (n = 275) of hospitalized SARS-CoV-2 polymerase chain reaction positive patients confirmed higher than expected numbers of blood group A individuals compared to O (RR = 1.24, CI 95% [1.05, 1.47], p = 0.0111). There was also a significant association between group A and COVID-19-related cardiovascular complications (RR = 2.56, CI 95% [1.43, 4.55], p = 0.0011) which is independent of gender. Molecular analysis revealed that group A non-secretors are significantly less likely to be hospitalized than secretors. Testing of convalescent plasma donors, among whom the majority displayed COVID-19 symptoms and only a small minority required hospitalization, group A non-secretors were slightly over-represented. Our findings showed that group A non-secretors are not resistant to infection by SARS-CoV-2, but are more likely to experience a less severe form of associated disease.
Collapse
Affiliation(s)
- Tosti J Mankelow
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK
| | - Belinda K Singleton
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK
| | - Pedro L Moura
- Center for Hematology and Regenerative Medicine Department of Medicine (MedH) Karolinska Institutet Stockholm Sweden
| | - Christian J Stevens-Hernandez
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.,School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK
| | - Nicola M Cogan
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK
| | - Gyongyver Gyorffy
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.,School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK
| | - Sabine Kupzig
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK
| | - Luned Nichols
- Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Claire Asby
- Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Jennifer Pooley
- Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Gabriella Ruffino
- Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Faroakh Hosseini
- Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Fiona Moghaddas
- Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Marie Attwood
- Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Alan Noel
- Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Alex Cooper
- Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - David T Arnold
- Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK
| | - Fergus Hamilton
- Infection Sciences, Southmead Hospital North Bristol NHS Trust Bristol UK.,Population Health Sciences University of Bristol Bristol UK
| | - Catherine Hyams
- Acute Medical Unit, Southmead Hospital North Bristol NHS Trust Bristol UK.,Academic Respiratory Unit Southmead Hospital North Bristol NHS Trust Bristol UK.,Population Health Sciences University of Bristol Bristol UK
| | - Adam Finn
- Cellular and Molecular Medicine Biomedical Sciences Building, University of Bristol Bristol UK.,Population Health Sciences University of Bristol Bristol UK.,Bristol Vaccine Centre University of Bristol Bristol UK
| | - Ashley M Toye
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.,School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK
| | - David J Anstee
- Bristol Institute for Transfusion Sciences (BITS) NHSBT, Filton Bristol UK.,NIHR Blood and Transplant Research Unit in Red Cell Products Bristol UK.,School of Biochemistry Biomedical Sciences Building University of Bristol Bristol UK
| |
Collapse
|